

EQA round: GP2/24 - Detection of Monoclonal Components

Deadline: 20.9.2024

Setup: minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	CVPG = consensus of the participants' groups	UL = upper limit
N _{tot} = total number of the results	U _{AV} = expanded uncertainty of the assigned value (k = 2)	N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Set 1 (plasma)														
(247) Gammopathies (quantity 1) (plasma)	[g/L]				90							90	84	93
Sample A1												90	86	96
All results		10,7	1,8	17	90	0	CVP	10,7	0,46	33%	7,16	14,3	90	
Sample B1												90	86	96
All results		25,9	2,9	11	90	1	CVP	25,9	0,76	33%	17,3	34,5	90	
(279) Total protein (plasma)	[g/L]				91							91	91	100
Sample A1												91	91	100
All results		54,3	1,2	2,3	91	0	CVP	54,3	0,32	8%	49,9	58,7	91	
Sample B1												91	91	100
All results		73,1	1,6	2,1	91	0	CVP	73,1	0,4	8%	67,2	79	91	
(314) FLC kappa (plasma)	[mg/L]				61							61	51	84
Sample A1												61	59	97
All results		5,45	0,79	15	61	0	CVP	5,45	0,25	±3	2,45	8,45	61	
Sample B1												61	53	87
All results		141	33	23	61	0	CVP	141	10	50%	70,5	212	61	
(315) FLC lambda (plasma)	[mg/L]				61							61	55	90
Sample A1												61	58	95
All results		10,1	1,6	16	61	0	CVP	10,1	0,51	50%	5,05	15,2	61	
Sample B1												61	57	93
All results		3,16	0,43	14	61	0	CVP	3,16	0,13	±3	0,16	6,16	61	
(318) Index kappa/lambda	[-]				58							58	47	81
Sample A1												58	56	97
All results		0,549	0,13	24	58	0	CVP	0,549	0,043	58%	0,23	0,868	58	
Sample B1												58	49	84
All results		42,8	14	34	58	0	CVP	42,8	4,6	58%	17,9	67,7	58	
Set 2 (urine)														
(545) Gammopathies (quantity 1) (urine)	[g/L]				36							36	28	78
Sample A2												36	31	86
All results		1,49	0,45	30	36	2	CVP	1,49	0,19	66%	0,506	2,48	36	
Sample B2												36	31	86
All results		0,332	0,15	45	36	1	CVP	0,332	0,062	66%	0,112	0,552	36	
(546) Gammopathies (quantity 2) (urine)	[g/L]				8							8	4	50
Sample A2												8	6	75
All results		1,93	0,93	48	8	1	CVP	1,93	0,9	66%	0,656	3,21	8	
Sample B2												8	4	50
All results		0,4	0,3	74	8	2	CVP	0,4	0,41	66%	0,136	0,664	8	
(547) Gammopathies (quantity 3) (urine)	[g/L]				14							14	14	100
Sample B2												14	14	100
All results		0,137	0,059	43	14	0	CVP	0,137	0,039	66%	0,046	0,228	14	
(550) Total protein (urine)	[g/L]				64							58	55	95
Sample A2												58	56	97
(1) Abbott		2,05	0,13	6,5	13	0	CVPG	2,05	0,091	30%	1,43	2,67	13	
(58) Beckman Coulter (AU)		3,22	0,31	9,6	10	0	CVPG	3,22	0,24	30%	2,25	4,19	10	
(60) Roche		2,1	0,12	5,6	24	1	CVPG	2,1	0,06	30%	1,47	2,73	24	
(162) Siemens (Atellica)		2,45	0,12	5	11	0	CVPG	2,45	0,09	30%	1,71	3,19	11	
Other					6	0							0	
								1x 0, 1x 12, 1x 75, 1x 158, 1x 178, 1x 179						
Sample B2		0,999	0,24	24	64							58	56	97
(1) Abbott		0,902	0,051	5,6	13	0	CVPG	0,902	0,034	30%	0,631	1,18	13	
(58) Beckman Coulter (AU)		1,31	0,088	6,7	10	0	CVPG	1,31	0,068	30%	0,917	1,71	10	
(60) Roche		0,799	0,044	5,5	24	0	CVPG	0,799	0,022	30%	0,559	1,04	24	
(162) Siemens (Atellica)		1,19	0,035	2,9	11	0	CVPG	1,19	0,026	30%	0,833	1,55	11	
Other					6	0							0	
								1x 0, 1x 12, 1x 75, 1x 158, 1x 178, 1x 179						